Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and

David A Tuveson1, Liqin Zhu, Aarthi Gopinathan

  • 1Department of Medicine, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania, USA. tuvesond@mail.med.upenn.edu

Cancer Research
|January 7, 2006
PubMed

Insights

Mist1-expressing cells can initiate pancreatic cancer when mutated with KrasG12D. These cells also contribute to liver cancer, suggesting a broader role in neoplasia.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oncogenic Kras mutations are common in early pancreatic ductal adenocarcinoma.
  • The specific cell type where Kras initiates pancreatic cancer is currently unknown.

Purpose of the Study:

  • To investigate the cellular origin of pancreatic tumorigenesis driven by oncogenic Kras.
  • To determine if Mist1-expressing cells are a potential site for Kras-initiated pancreatic cancer.

Main Methods:

  • Gene targeting of KrasG12D into the Mist1 gene in mice.
  • Analysis of pancreatic and hepatic neoplasia development in Mist1(KrasG12D/+) mutant mice.
  • Assessment of the impact of concomitant Trp53+/- mutation.

Main Results:

  • Mist1(KrasG12D/+) mice developed invasive, metastatic pancreatic cancer with mixed histologic features.
  • Hepatocellular carcinoma developed in many mutant mice, indicating Mist1(KrasG12D/+) cells' role in hepatic neoplasia.
  • Trp53+/- mutation accelerated lethality and advanced histopathology, including liver metastasis.

Conclusions:

  • Mist1-expressing cells are a permissive compartment for oncogenic Kras-driven pancreatic tumorigenesis.
  • Mist1-expressing cells contribute to both pancreatic and hepatic neoplasia.
  • Targeting Mist1-expressing cells may offer a therapeutic strategy for Kras-driven cancers.

Related Concept Videos